Tempus AI Stock Gains on Piper Sandler Upgrade to Overweight

Shares of Tempus AI (NASDAQ:TEM) rose in premarket trading Tuesday after Piper Sandler upgraded the company's stock to Overweight from a previous Neutral rating. The analyst, David Westenberg, also significantly increased the price target on the stock to $76 from $56.

In a note to clients, Piper Sandler reported that Tempus AI shares climbed 2.1% in premarket activity following the ratings change. The upgrade reflects a shift in the analyst's view, which previously held that the stock's valuation was largely influenced by general sentiment around artificial intelligence rather than the performance of its core businesses.

Key Catalysts for Upgraded Outlook

Westenberg identified three specific growth drivers that have become clearer, prompting the more optimistic rating. These catalysts provide a more tangible basis for the company's valuation beyond the AI theme.

The key factors cited by Piper Sandler include:

Ad

• Personalis Acquisition: The pending acquisition is set to provide Tempus with a "differentiated tumor-informed MRD platform," a critical tool in cancer diagnostics for detecting minimal residual disease.
• Positive Trial Data: A positive readout from the INTerpath-001 trial enhances the strategic value of both Personalis and Tempus AI as the tumor sequencing provider for what could be a new class of therapeutics.
• Regulatory and Pricing Momentum: Recent FDA approval for the company's tumor-only xT CDx test clears a major hurdle, allowing Tempus to pursue unified Advanced Diagnostic Laboratory Test (ADLT) pricing. The firm sees a similar path for the xF test in the second half of 2027.

Investor Implications

The upgrade suggests growing analyst confidence in the fundamental drivers of Tempus AI's diagnostics and data segments. For investors, this marks a potential shift in the narrative from a company valued on AI potential to one with a clearer, more defined pathway to commercial and financial growth through specific products and strategic acquisitions.